Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Basilea Pharmaceutica AG (0QNA) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Basilea Pharmaceutica AG £113, price £66.80, upside +69.0%, quality 69 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? Yes
- Add to watchlist
BP
Broad data
Sep 24, 2026
Basilea Pharmaceutica AG
0QNA · LSEClearly undervaluedStrong Fair Value upside, but quality is only moderate.
✓Fair value £112.88 · Strongly undervalued (+69.0%)
✓Quality 69/100
✓Healthy Growth (revenue 5y +12.7 %/yr)
✓Solidly profitable · 17.3% net margin (TTM)
!High debt · generates free cash flow
✓Wide moat 76/100
!The models disagree: range £49.71 to £221.58
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range £30.00 – £69.90 · fair‑value band £49.71 – £221.58 · the £66.80 price screens below the £112.88 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Company profile
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
Show more
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), acute bacterial skin, community-acquired bacterial pneumonia, and skin structure infections (ABSSSI). The company also has a clinical-stage pipeline of anti-infective assets that include fosmanogepix, a broad-spectrum antifungal in phase 3 development for invasive mold infections; ceftibuten-ledaborbactam etzadroxil, a phase 3 - ready oral antibiotic for the treatment of complicated urinary tract infections (cUTI); BAL2062, a candidate for invasive aspergillosis currently advancing toward phase 2 clinical development; and BAL2420, a preclinical-stage antibiotic targeting severe enterobacteriaceae infections. The company has a strategic collaboration with Prokaryotics, Inc for the development of broad-spectrum antifungal targeting drug-resistant pathogens through a differentiated mechanism of action; and Phare Bio, a biotech social venture to leverage generative artificial intelligence (AI) to transform antibiotic discovery. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
Stock analysis
Basilea Pharmaceutica AG (0QNA) currently trades at £66.80, while our model-based Fair Value estimate is £112.88, implying the stock looks roughly 40.8% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of £171.83 per share, and 15 of the 24 models we run sit above the £66.80 price.
Bear case: the Economic Profit group reads lowest at £29.59, and 9 of the 24 models stay below the price. Evidence for this calculation is high.
Scenario range: £49.71 (bear) to £221.58 (bull), the price of £66.80 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Basilea Pharmaceutica AG reported revenue of £232M in FY2025 versus £148M in FY2021, a compound +11.9%/yr. Reported net income was £40.2M in FY2025.
Key figures
Market cap £855M · P/S ratio 2.46 · EPS (TTM) £−0.5850 · Net margin 17.3% · Return on equity 38.5% · Return on assets (EBIT) 12.5% · Operating margin 21.7% · Revenue (TTM) £232M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 4% below its 52-week high and 49% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 69%, 0QNA screens cheaper than that median.
Fair Value models
Bear £49.71
Fair Value £112.88
Bull £221.58
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV
£14.53
£19.15
£23.00
74
FCF DCF
£58.90
£94.86
£202.35
73
Growth DCF
£53.95
£107.34
£191.21
73
All 24 models by family
DCF Models
FCF DCF
£58.90
£94.86
£202.35
73
Owner Earnings
£32.60
£88.29
£191.61
67
5Y Revenue Exit
£37.76
£74.74
£151.75
66
5Y EBITDA Exit
£42.69
£84.71
£166.87
68
5Y P/E Exit
£47.93
£123.02
£223.96
64
10Y Revenue Exit
£43.55
£106.62
£143.27
64
10Y EBITDA Exit
£48.48
£116.31
£229.92
62
10Y P/E Exit
£51.98
£126.60
£246.02
58
Earnings-Based
Graham-Dodd
£25.15
£175.39
£246.13
61
Lynch FV
£90.61
£129.44
£168.28
59
PEG = 1.0
£90.61
£129.44
£168.28
55
EPV
£14.53
£19.15
£23.00
74
Multiples
P/E Multiple
£61.02
£81.36
£101.71
63
P/S Multiple
£47.15
£62.87
£78.59
58
P/B Multiple
£39.73
£52.97
£66.21
55
EV/EBIT
£41.20
£61.38
£81.56
65
EV/EBITDA
£34.11
£51.92
£69.73
66
EV/Revenue
£23.88
£42.39
£60.91
52
Asset-Based
NCAV (Graham)
£5.89
£7.89
£11.77
54
Growth DCF
Growth DCF
£53.95
£107.34
£191.21
73
Rev-Margin DCF
£43.40
£88.30
£182.53
65
Economic Profit
Residual Income
£20.66
£30.93
£67.50
62
ROIC Compounder
£17.52
£29.59
£39.84
68
Growth Earnings
Growth-Adj P/E
£120.28
£171.83
£223.38
65
Notify me when 0QNA reaches fair value
Put 0QNA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
69/100
Of which business quality 66 · Market factors (momentum, volatility) 78
Profitability
83
Margins and returns on capital today
Quality Growth
36
Are margins and returns improving?
Cashflow
90
Earnings quality: real cash, not paper profit
Fin. Strength
31
Balance sheet, leverage, solvency risk
Investment
79
Disciplined investing over empire-building
Low Volatility
85
Calm price path (market factor)
Momentum
72
Price trend over the last 3–12 months (market factor)
52W Momentum
79
Distance to the 52-week high (market factor)
Net Issuance
80
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
97/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+11.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.7%
Start year 2020 (pandemic). Over 10 years: +16.2% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+66.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+66.8%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−18% → 22%
2025 sits 209% above its own trend. The rate follows the median trend of the last 3 years, not that single year.
Growth Forecast
Price in line with expectations
The price assumes less growth than the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+6.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (UK: IMF forecast 2.3% a year to 2030, 3.3% from 2016 to 2025) that is about +4.1% a year for the price and +1.6% for the forecasts.
Forecast 2026 (sales)+13.1%
Forecast 2027 (sales)+1.7%
Projected 2028 (sales)+1.8%
Projected 2029 (sales)+1.8%
Projected 2030 (sales)+1.8%
Watch 0QNA, get fair value alerts →
Compare Basilea Pharmaceutica AG with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Context: sector, industry, market
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: UK Stocks
- Valuation of the UK market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $527.67 | $580.44 | +10% |
| Regeneron Pharmaceuticals, Inc REGN | $752.25 | $1,275 | +69% |
| argenx SE ARGX | $959.49 | $918.60 | −4% |
| CSL Limited CSL | A$175.35 | A$192.89 | +10% |
| Samsung Biologics Co 207940 | 1,354,000 KRW | 1,489,400 KRW | +10% |
| BeOne Medicines AG ONC | $360.85 | $280.94 | −22% |
| Alnylam Pharmaceuticals, Inc ALNY | $255.96 | $217.88 | −15% |
| Royalty Pharma plc RPRX | $58.21 | $19.01 | −67% |
| Celltrion, Inc 068270 | 177,400 KRW | 74,519 KRW | −58% |
| WuXi Biologics (Cayman) Inc 2269 | HK$53.00 | HK$58.30 | +10% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Basilea Pharmaceutica AG (0QNA) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of £112.88 versus a price of £66.80, about +69% upside (undervalued).
What is the fair value of 0QNA?
Our model-based fair value for Basilea Pharmaceutica AG is £112.88 (as of Sep 24, 2026), built from audited fundamentals. The current price: £66.80.
What is the quality score of 0QNA?
Basilea Pharmaceutica AG has a Quality Score of 69/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Basilea Pharmaceutica AG (0QNA)?
Our model-based price target is the fair value of £112.88 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario £49.71, optimistic scenario £221.58. It is a calculation from audited fundamentals, not an analyst target.
What is the Basilea Pharmaceutica AG stock forecast for 2026?
Our models put fair value at £112.88, about +69% upside versus a price of £66.80 (undervalued). Cautious scenario £49.71, optimistic scenario £221.58. The calculation is refreshed regularly with new filings.
What is the revenue of Basilea Pharmaceutica AG (0QNA)?
Basilea Pharmaceutica AG reported trailing-twelve-month revenue of about £232M (latest available figure, as of Sep 24, 2026).
What growth is priced into Basilea Pharmaceutica AG (0QNA)?
For today's price to be fair in a discounted-cash-flow model, Basilea Pharmaceutica AG would have to grow free cash flow by +6.5 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.7 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 0QNA use?
Our models discount Basilea Pharmaceutica AG at 10.3 %: a base by market capitalisation (small), damped by beta 0.42, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Basilea Pharmaceutica AG that is +6.5 % per year a year over ten years, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has Basilea Pharmaceutica AG (0QNA) delivered so far?
Over the past 5 years revenue at Basilea Pharmaceutica AG grew +12.7 % a year. The price currently implies +6.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Basilea Pharmaceutica AG (0QNA) growing?
The median revenue growth in the sector is +7.3 % a year. That is the yardstick for the growth priced into Basilea Pharmaceutica AG (+6.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Basilea Pharmaceutica AG (0QNA)?
The free-cash-flow yield on the price is 6.95 %: that much free cash flow Basilea Pharmaceutica AG produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Basilea Pharmaceutica AG (0QNA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Basilea Pharmaceutica AG it is £112.88 per share (as of Sep 24, 2026), against a price of £66.80. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Basilea Pharmaceutica AG stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0QNA trades below its calculated fair value: price £66.80, fair value £112.88, a gap of about +69% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0QNA?
No. The price is what the market pays today (£66.80); the fair value is what the company's own numbers justify (£112.88). For Basilea Pharmaceutica AG the two are £46.08 per share apart. That gap is exactly why we show both numbers side by side.
How much is Basilea Pharmaceutica AG worth?
The market values Basilea Pharmaceutica AG at about £855M (market capitalisation, as of Sep 24, 2026). Per share that is £66.80; our models calculate a fair value of £112.88 per share.
What do the bullish and bearish scenarios say about 0QNA?
Our models span a range for Basilea Pharmaceutica AG: cautious scenario £49.71, base £112.88, optimistic £221.58 per share (as of Sep 24, 2026, price £66.80). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0QNA from its 52-week high?
Basilea Pharmaceutica AG trades at £66.80, about 4% below its 52-week high of £69.90 and 49% above the low of £44.70 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of £112.88 is for.
Which stocks are comparable to Basilea Pharmaceutica AG?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Basilea Pharmaceutica AG stock attractive at the current price?
The data as of Sep 24, 2026: price £66.80, calculated fair value £112.88 (+69%), Quality Score 69/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0QNA calculated?
We run Basilea Pharmaceutica AG through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of £112.88, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Basilea Pharmaceutica AG currently trades 41 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Basilea Pharmaceutica AG (0QNA)?
The closing price on Oct 2, 2026 was £66.80. Our model-based fair value is £112.88, about +69% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Basilea Pharmaceutica AG right now?
The model range is unusually wide (£49.71 to £221.58). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid quality (69/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Basilea Pharmaceutica AG
How large is the market capitalisation of Basilea Pharmaceutica AG (0QNA)?
The market capitalisation of Basilea Pharmaceutica AG is £855M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Basilea Pharmaceutica AG (0QNA)?
The price-to-sales ratio of Basilea Pharmaceutica AG is 2.46 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Basilea Pharmaceutica AG (0QNA)?
Earnings per share at Basilea Pharmaceutica AG are £−0.5850. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Basilea Pharmaceutica AG (0QNA)?
The net margin of Basilea Pharmaceutica AG is 17.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Basilea Pharmaceutica AG (0QNA)?
The return on equity (ROE) of Basilea Pharmaceutica AG is 38.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Basilea Pharmaceutica AG (0QNA)?
On an EBIT basis the return on assets of Basilea Pharmaceutica AG is 12.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Basilea Pharmaceutica AG (0QNA)?
The operating margin of Basilea Pharmaceutica AG is 21.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Basilea Pharmaceutica AG (0QNA)?
Revenue at Basilea Pharmaceutica AG is growing −2.9% versus a year earlier (3y avg +16.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Basilea Pharmaceutica AG (0QNA)?
Earnings per share at Basilea Pharmaceutica AG are growing −55.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Basilea Pharmaceutica AG (0QNA) carry?
The net debt of Basilea Pharmaceutica AG is £59.6M (fiscal year 2025, ≈ 1.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
Open the live analysis →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.